(RTTNews) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy targeting claudin-1 for the treatment of rare kidney, liver and other diseases, CSL said in a
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.